×
S&P 500   3,844.97 (-1.41%)
DOW   31,142.30 (-0.94%)
QQQ   285.24 (-2.47%)
AAPL   138.59 (-2.17%)
MSFT   258.38 (-2.46%)
META   163.11 (-3.76%)
GOOGL   2,242.37 (-3.21%)
AMZN   107.87 (-4.73%)
TSLA   701.22 (-4.56%)
NVDA   160.35 (-4.94%)
NIO   22.30 (-2.83%)
BABA   116.97 (-1.48%)
AMD   80.85 (-6.16%)
MU   58.48 (-0.51%)
CGC   3.61 (-4.75%)
T   20.70 (-0.38%)
GE   65.75 (-1.44%)
F   11.92 (-1.00%)
DIS   97.17 (+0.58%)
AMC   13.57 (-3.96%)
PFE   50.51 (-2.64%)
PYPL   72.57 (-4.44%)
NFLX   181.83 (-3.86%)
S&P 500   3,844.97 (-1.41%)
DOW   31,142.30 (-0.94%)
QQQ   285.24 (-2.47%)
AAPL   138.59 (-2.17%)
MSFT   258.38 (-2.46%)
META   163.11 (-3.76%)
GOOGL   2,242.37 (-3.21%)
AMZN   107.87 (-4.73%)
TSLA   701.22 (-4.56%)
NVDA   160.35 (-4.94%)
NIO   22.30 (-2.83%)
BABA   116.97 (-1.48%)
AMD   80.85 (-6.16%)
MU   58.48 (-0.51%)
CGC   3.61 (-4.75%)
T   20.70 (-0.38%)
GE   65.75 (-1.44%)
F   11.92 (-1.00%)
DIS   97.17 (+0.58%)
AMC   13.57 (-3.96%)
PFE   50.51 (-2.64%)
PYPL   72.57 (-4.44%)
NFLX   181.83 (-3.86%)
S&P 500   3,844.97 (-1.41%)
DOW   31,142.30 (-0.94%)
QQQ   285.24 (-2.47%)
AAPL   138.59 (-2.17%)
MSFT   258.38 (-2.46%)
META   163.11 (-3.76%)
GOOGL   2,242.37 (-3.21%)
AMZN   107.87 (-4.73%)
TSLA   701.22 (-4.56%)
NVDA   160.35 (-4.94%)
NIO   22.30 (-2.83%)
BABA   116.97 (-1.48%)
AMD   80.85 (-6.16%)
MU   58.48 (-0.51%)
CGC   3.61 (-4.75%)
T   20.70 (-0.38%)
GE   65.75 (-1.44%)
F   11.92 (-1.00%)
DIS   97.17 (+0.58%)
AMC   13.57 (-3.96%)
PFE   50.51 (-2.64%)
PYPL   72.57 (-4.44%)
NFLX   181.83 (-3.86%)
S&P 500   3,844.97 (-1.41%)
DOW   31,142.30 (-0.94%)
QQQ   285.24 (-2.47%)
AAPL   138.59 (-2.17%)
MSFT   258.38 (-2.46%)
META   163.11 (-3.76%)
GOOGL   2,242.37 (-3.21%)
AMZN   107.87 (-4.73%)
TSLA   701.22 (-4.56%)
NVDA   160.35 (-4.94%)
NIO   22.30 (-2.83%)
BABA   116.97 (-1.48%)
AMD   80.85 (-6.16%)
MU   58.48 (-0.51%)
CGC   3.61 (-4.75%)
T   20.70 (-0.38%)
GE   65.75 (-1.44%)
F   11.92 (-1.00%)
DIS   97.17 (+0.58%)
AMC   13.57 (-3.96%)
PFE   50.51 (-2.64%)
PYPL   72.57 (-4.44%)
NFLX   181.83 (-3.86%)
NASDAQ:TCRR

TCR2 Therapeutics Stock Forecast, Price & News

$2.85
-0.04 (-1.38%)
(As of 06/28/2022 01:17 PM ET)
Add
Compare
Today's Range
$2.82
$2.90
50-Day Range
$2.11
$2.89
52-Week Range
$2.07
$19.03
Volume
4,480 shs
Average Volume
608,079 shs
Market Capitalization
$109.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.38
30 days | 90 days | 365 days | Advanced Chart

Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Stock Forecast (MarketRank)

Overall MarketRank

2.46 out of 5 stars

Medical Sector

157th out of 1,436 stocks

Biological Products, Except Diagnostic Industry

26th out of 217 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -
TCR2 Therapeutics logo

About TCR2 Therapeutics (NASDAQ:TCRR)

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

TCRR Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCRR
Fax
N/A
Employees
137
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
6/28/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$17.38
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+509.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.625
Research Coverage
8 Analysts

Profitability

Net Income
$-99.81 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.36 per share

Miscellaneous

Free Float
29,237,000
Market Cap
$109.87 million
Optionable
Not Optionable
Beta
2.21














TCR2 Therapeutics Frequently Asked Questions

Should I buy or sell TCR2 Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TCR2 Therapeutics stock.
View analyst ratings for TCR2 Therapeutics
or view top-rated stocks.

What is TCR2 Therapeutics' stock price forecast for 2022?

8 equities research analysts have issued twelve-month price targets for TCR2 Therapeutics' shares. Their TCRR stock forecasts range from $5.00 to $38.00. On average, they predict TCR2 Therapeutics' share price to reach $17.38 in the next year. This suggests a possible upside of 509.6% from the stock's current price.
View analysts' price targets for TCR2 Therapeutics
or view top-rated stocks among Wall Street analysts.

How has TCR2 Therapeutics' stock price performed in 2022?

TCR2 Therapeutics' stock was trading at $4.66 at the beginning of 2022. Since then, TCRR stock has decreased by 38.8% and is now trading at $2.85.
View the best growth stocks for 2022 here
.

When is TCR2 Therapeutics' next earnings date?

TCR2 Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for TCR2 Therapeutics
.

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) released its earnings results on Thursday, May, 12th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.02.
View TCR2 Therapeutics' earnings history
.

Who are TCR2 Therapeutics' key executives?

TCR2 Therapeutics' management team includes the following people:
  • Dr. Garry E. Menzel M.B.A., Ph.D., Pres, CEO & Director (Age 58, Pay $916.8k)
  • Dr. Patrick A. Baeuerle Ph.D., Founder & Member of the Advisory Board (Age 64, Pay $47.02k)
  • Mr. Peter Olagunju, Chief Technical Officer (Age 44, Pay $307.42k)
  • Dr. Alfonso Quintas Cardama M.D., Chief Medical Officer (Age 51, Pay $668.6k)
  • Mr. Richard Roomberg, VP of Corp. Controller
  • Carl Mauch, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Margaret Siegel J.D., Head of Legal & Corp. Sec.
  • Dr. Angela Justice Ph.D., Chief People Officer (Age 48)
  • Dr. Rosemary Harrison Ph.D., Chief Bus. & Strategy Officer (Age 39)
  • Mr. Stephen Turkowiak M.B.A., VP of Fin. & Treasurer

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are TCR2 Therapeutics' major shareholders?

TCR2 Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.57%), Renaissance Technologies LLC (3.74%), Vanguard Group Inc. (2.67%), JPMorgan Chase & Co. (1.85%), State Street Corp (1.36%) and Acadian Asset Management LLC (1.24%). Company insiders that own TCR2 Therapeutics stock include Mayur Ian Somaiya, Morana Jovan-Embiricos, Neil W Gibson and Robert Hofmeister.
View institutional ownership trends for TCR2 Therapeutics
.

Which institutional investors are selling TCR2 Therapeutics stock?

TCRR stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Vanguard Group Inc., JPMorgan Chase & Co., Goldman Sachs Group Inc., BNP Paribas Arbitrage SA, Northern Trust Corp, Harbor Capital Advisors Inc., and Bank of New York Mellon Corp. Company insiders that have sold TCR2 Therapeutics company stock in the last two years include Mayur Ian Somaiya, and Robert Hofmeister.
View insider buying and selling activity for TCR2 Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying TCR2 Therapeutics stock?

TCRR stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC, Prudential Financial Inc., BlackRock Inc., GSA Capital Partners LLP, Sawtooth Solutions LLC, XTX Topco Ltd, and Private Advisor Group LLC.
View insider buying and selling activity for TCR2 Therapeutics
or or view top insider-buying stocks.

How do I buy shares of TCR2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $2.85.

How much money does TCR2 Therapeutics make?

TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $109.87 million. The company earns $-99.81 million in net income (profit) each year or ($2.81) on an earnings per share basis.

How many employees does TCR2 Therapeutics have?

TCR2 Therapeutics employs 137 workers across the globe.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for TCR2 Therapeutics is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at [email protected].

This page (NASDAQ:TCRR) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.